Last updated: 23 January 2023 at 9:03pm EST

Yossi Maimon CPA, M.B.A., CPA, MBA Net Worth




The estimated Net Worth of Yossi Maimon is at least $806 Thousand dollars as of 14 December 2015. Mr Maimon owns over 10,000 units of Ayala Pharmaceuticals stock worth over $5,000 and over the last 17 years he sold AYLA stock worth over $108,842. In addition, he makes $692,182 as CFO and Sec. & Treasurer at Ayala Pharmaceuticals.

Mr MBA AYLA stock SEC Form 4 insiders trading

Mr has made over 9 trades of the Ayala Pharmaceuticals stock since 2008, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of AYLA stock worth $7,800 on 14 December 2015.

The largest trade he's ever made was exercising 167,698 units of Ayala Pharmaceuticals stock on 15 October 2009 worth over $162,667. On average, Mr trades about 32,798 units every 136 days since 2008. As of 14 December 2015 he still owns at least 10,000 units of Ayala Pharmaceuticals stock.

You can see the complete history of Mr Maimon stock trades at the bottom of the page.





Mr. Yossi Maimon CPA, M.B.A., CPA, MBA biography

Yossi Maimon CPA, M.B.A., CPA, MBA is the CFO, Sec. & Treasurer at Ayala Pharmaceuticals.

What is the salary of Mr MBA?

As the CFO and Sec. & Treasurer of Ayala Pharmaceuticals, the total compensation of Mr MBA at Ayala Pharmaceuticals is $692,182. There are no executives at Ayala Pharmaceuticals getting paid more.



How old is Mr MBA?

Mr MBA is 50, he's been the CFO and Sec. & Treasurer of Ayala Pharmaceuticals since . There are 3 older and 1 younger executives at Ayala Pharmaceuticals. The oldest executive at Ayala Pharmaceuticals, Inc. is Dr. Gary B. Gordon M.D., Ph.D., 68, who is the Chief Medical Officer.

Insiders trading at Ayala Pharmaceuticals

Over the last 4 years, insiders at Ayala Pharmaceuticals have traded over $930,844 worth of Ayala Pharmaceuticals stock and bought 1,575,250 units worth $23,628,700 . The most active insiders traders include Growth Fund Limited Partner..., Murray A Goldberg, and Growth Fund Limited Partner.... On average, Ayala Pharmaceuticals executives and independent directors trade stock every 37 days with the average trade being worth of $102,203. The most recent stock trade was executed by Gary B. Gordon on 24 February 2021, trading 3,000 units of AYLA stock currently worth $15,480.



What does Ayala Pharmaceuticals do?

Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.



What does Ayala Pharmaceuticals's logo look like?

Ayala Pharmaceuticals, Inc. logo

Complete history of Mr Maimon stock trades at Protalix BioTherapeutics and Ayala Pharmaceuticals

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
14 Dec 2015 Yossi Maimon
Vice President and Chief Financial Officer
Buy 10,000 $0.78 $7,800
14 Dec 2015
10,000
2 May 2012 Yossi Maimon
Vice President and Chief Financial Officer
Option 125,964 $1.64 $206,581
2 May 2012
125,964
7 Oct 2010 Yossi Maimon
Vice President and Chief Financial Officer
Option 77,769 $0.97 $75,436
7 Oct 2010
0
3 Sep 2010 Yossi Maimon
Vice President and Chief Financial Officer
Option 70,000 $0.97 $67,900
3 Sep 2010
0
15 Oct 2009 Yossi Maimon
Vice President and Chief Financial Officer
Option 167,698 $0.97 $162,667
15 Oct 2009
0
6 Jul 2009 Yossi Maimon
Vice President and Chief Financial Officer
Option 62,217 $0.97 $60,350
6 Jul 2009
0
18 May 2009 Yossi Maimon
Vice President and Chief Financial Officer
Option 40,348 $0.97 $39,138
18 May 2009
40,348
13 Mar 2009 Yossi Maimon
Vice President and Chief Financial Officer
Sale 48,590 $2.24 $108,842
13 Mar 2009
0
22 Feb 2008 Yossi Maimon
Vice President and Chief Financial Officer
Option 86,176 $0.97 $83,591
22 Feb 2008
86,176


Ayala Pharmaceuticals executives and stock owners

Ayala Pharmaceuticals executives and other stock owners filed with the SEC include: